<?xml version="1.0" encoding="UTF-8"?>
<ref id="B69-pharmaceuticals-12-00101">
 <label>69.</label>
 <element-citation publication-type="book">
  <person-group person-group-type="author">
   <name>
    <surname>Robert-Gero</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Lawrence</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Lederer</surname>
    <given-names>E.</given-names>
   </name>
  </person-group>
  <article-title>Potential Clinical Use of Sinefungin: Reduction of Toxicity and Enhancement of Activity</article-title>
  <source>Leishmaniasis</source>
  <series>NATO ASI Series (Series A: Life Sciences)</series>
  <person-group person-group-type="editor">
   <name>
    <surname>Hart</surname>
    <given-names>D.T.</given-names>
   </name>
  </person-group>
  <publisher-name>Springer</publisher-name>
  <publisher-loc>Boston, MA, USA</publisher-loc>
  <year>1989</year>
  <volume>Volume 171</volume>
 </element-citation>
</ref>
